This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.
In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.
A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.
Low-dose rivaroxaban plus aspirin reduced the risk for stroke in patients with CAD or PAD, especially in those with prior stroke, as shown in a subanalysis of the COMPASS trial.
A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.
A post-hoc analysis of ENGAGE AF-TIMI 48 showed comparable efficacy, favorable safety, and better net clinical outcomes with edoxaban vs. warfarin in Asians, compared to non-Asians.
This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.
This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.
In a quantitative modeling study, statins provided net benefit at higher 10-year risks for CVD than seen in most guidelines. The level of CVD risk at which net benefit occurs depends on age, sex, and statin type.
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.
A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.